StressMarq Biosciences is a leading provider of high-quality fibrillar, oligomeric, and monomeric protein preparations—including alpha synuclein, tau, amyloid beta, TDP-43, SOD1,TTR and more—designed to support cutting-edge neurodegenerative disease research. With a focus on pathology-inducing protein aggregates, our products support the development of robust disease models and accelerate drug discovery for conditions such as Alzheimer’s, Parkinson’s, and ALS. StressMarq is committed to scientific excellence— empowering researchers worldwide with tools that accelerate discovery and translational research.

TDP-43 Monomers

TAR DNA-binding protein 43 (TDP-43) is a key pathological hallmark in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). TDP-43 is a ubiquitously expressed RNA/DNA-binding protein that plays a pivotal role in RNA processing, including RNA splicing, mRNA turnover, and microRNA biogenesis. Its pathological mislocalization from the nucleus to the cytoplasm, accompanied by aggregation and post-translational modifications, is a hallmark of several neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), and Alzheimer’s disease. These TDP-43 proteinopathies disrupt nucleocytoplasmic transport and mitochondrial function, contributing to neuronal dysfunction and death. Recent studies have also highlighted TDP-43’s involvement in DNA repair and chromatin remodeling, expanding its relevance in neurobiology beyond RNA processing. Notably, Pokrishevsky et al. (2024) demonstrated that when all six tryptophans are mutated to serines (trpless), this significantly reduces the protein’s ability to cross-seed SOD1 aggregation.

StressMarq manufactures TDP-43 Hexamutant (W→S) Monomers for use in neurodegenerative disease research. These TDP-43 hexamutant monomers demonstrate a decreased propensity to aggregate.

• Human Recombinant TDP-43 Hexamutant Monomers | catalog# SPR-522

Supplemental Learning Materials

Technical Support Resources

• Handling Instructions | TDP-43
• Protocols | Neuro Proteins
• Sonication Protocol | PFFs
• Frequently Asked Questions | Neuro Proteins

Selected Publications from the StressMarq Blog

• TDP-43 and neurodegeneration: Unraveling protein aggregation | September 2025 | Scientific Review
• MOK protein kinase controls microglial response in Amyotrophic Lateral Sclerosis (ALS) | August 2023 | Product Citation Reviews
• SOD1 Aggregation in Amyloid Lateral Sclerosis (ALS) | June 2019| Scientific Review

Have a question about TDP-43?